Description: Artery Therapeutics, Inc. (ARTERY) is a pre-clinical stage biotechnology company developing effective treatments for neurodegenerative and metabolic diseases.
diabetes (2636) heart (1364) cure (558) alzheimer's (397) therapeutics (84) apoe4 (2) abca1 (1)
Publications
Artery Therapeutics, Inc. (Artery), a biotechnology company headquartered in the San Francisco Bay area, develops proprietary therapeutics for mainly neurodegenerative diseases including apolipoprotein E (ApoE4) associated dementia and Alzheimer's disease. Artery¹s novel peptide library is derived from ApoE. Our safe and effective peptides are designed to manipulate the ABCA1 (ATP-binding cassette) transporter, thereby altering cell membrane composition and functionality of monocyte-macrophage cells includi
The ABCA1 transporter was discovered in 1999; the six trans-membrane ABCs transport lipids, ions, and drugs across extra- and intracellular membranes, affecting signal transduction, endo- and exocytosis, and vesicular trafficking with effects on several disease states.